AGP Executive Report
Last update: 10 hours agoRare disease drug approval: The European Commission has granted marketing authorisation for NEZGLYAL® (leriglitazone) for childhood cerebral adrenoleukodystrophy (cALD) in male patients aged 2–12 with Gd-negative brain lesions—the first pharmacological treatment for early intervention in the EU, with an initial launch expected in Germany by year-end. Biotech access & sales watch: Neuren is moving toward first commercial sales in Europe after the EU approval of its Rett syndrome treatment Daybu (trofinetide), which covers EU countries including Liechtenstein. US tariff relief for specialty medicines: The US Commerce Department clarified which specialty pharmaceutical products and ingredients can qualify for zero tariffs ahead of a September 29 deadline; eligibility depends on product type and specific trade/security or urgent health need pathways. Public health signal (Switzerland): Switzerland reported 544 TB infections in 2025 (including Liechtenstein), the highest since 2018, driven largely by people of foreign origin.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
